Study S003290

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-WEEKLY BEROBENATIDE IN ADULTS WITH OBESITY DISEASE IN JAPAN (VESPER-JW)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07794761
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: NOT_YET_RECRUITING
Enrollment: 180
Start: 2026-09-28
Primary completion: 2029-03-14
Lead sponsor: Pfizer
Conditions: Obesity
Interventions: DRUG:Berobenatide; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:VESPER-JW

Registered primary outcomes

Percent change from baseline in body weight [Baseline, Week 72]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.